• Lenin Fernandes posted an article

    Opinion: Seattle's VC ecosystem should capitalize on homegrown startups

    Opinion: Seattle's VC ecosystem should capitalize on homegrown startups see more

    By  Nathan McDonald Keiretsu Capital

    Dec 3, 2020, 5:00am PST

    When it comes to supporting entrepreneurs and innovation, Seattle is punching well below its weight. Despite its reputation as a technology and innovation hub Seattle is only the fifth largest market for VC investing. It is time for Seattle to increase local venture stage funding, with a fundamental change in culture and allocation toward investing and backing local companies and entrepreneurs.

    Based on just the consolidation of capital, Seattle realistically cannot compete with the Bay Area or New York, but there's no reason why Seattle cannot have a comparable funding ecosystem similar to a city like Boston.

    Part of the funding challenge is the Northwest has failed to develop its professional financial services industry to cultivate and retain deal making investment talent. Seattle has never had a homegrown financial services company that has not been acquired or bought by an out-of-town company.

    As such, the decision-making for those investments and financial decisions goes out of town with it. Seattle is always going to underachieve if the status quo remains, and that is not a winning formula to deliver on the full potential of our local entrepreneurs. We need to allocate capital to back and build our financial talent base to create the leverage needed to scale to compete with markets like Boston.

    To truly compete, we need to cultivate a shift toward family office investment structures which allow for attracting and expanding our direct investment talent pool and back funds that reinvest locally. As I've traveled around the country and encountered different financial ecosystems, my experience has been the difference in those areas is the fierce commitment to allocate capital to this risk class.

    Seattle does a great job at the seed level and has an active angel community. That said, it takes a network of groups working together with family offices to build an investment syndicate with enough capital for a Series A round and beyond when you need to raise four, six or ten million dollars. Family offices working together with angels and fund managers are the key to dramatically increasing growth capital available from our local wealth.

    A different mindset is required, with investors thinking and allocating in 10- to 20-year commitments and investing in building the financial talent base we need to achieve our potential. This requires a family office structure to allocate the capital and the full resources required to choose and support the investments. This is standard practice with family offices in New York, Boston, California, where the proper infrastructure is in place. For them, it's not a matter of whether there is wealth to support that private deal making infrastructure, it’s a matter of whether there's someone who really wants the deal to happen or not.

    The current climate for those investments could not be better. Looking at the local landscape, investors will see a robust, high-quality deal flow that, despite the pandemic, offers a torrent of exciting opportunities to invest in game-changing innovations in technology and life sciences in particular. Companies that are creating the future are all around us in our community.

    We are finding family offices work well together with the talent and expertise of angel groups. We have all the ingredients to grow this combination of talent and capital right here, right now. We can partner and bring in add-on growth capital at the inflection point when the company has proven out their product and market fit. The family office collaboration with angel investors provides a very scalable, workable marketplace solution for capital to flow, companies to perform and financing rounds to get done. Growing and expanding our financial professional talent base creates a virtuous cycle of growth, wealth creation and reallocation to risk.

    In Seattle, we're seeing more companies that have been family-owned businesses for a long time exiting for hundreds of millions of dollars. High-net worth family capital is fast changing hands to the next generation.

    Will there be a renewed allocation toward local investing talent and the structures that drive them, or will we continue to outsource those investment decisions and hire professionals outside of the region to make those investment decisions for us?




     December 03, 2020
  • Article

    MedTech Outlook Selects OtoNexus as one of the top 10 Infection Control Solution Provider for 2020

    OtoNexus Medical Technologies at the Forefront of Providing Infection Control Solution see more

    SEATTLE, Oct. 1, 2020 /PRNewswire/ -- OtoNexus Medical Technologies Inc. announced today that MedTech Outlook selected them as one of 10 companies nationwide that are at the forefront of providing infection control solutions and having an impact on the industry.

    OtoNexus has developed the world's first ultrasound hand-held device to evaluate the four disease states of middle ear infection.  With the tools available today, detection accuracy is approximately 50% in the critical differentiation of viral versus bacterial infections.  As a result, middle ear infections are the #1 reason for antibiotic prescriptions and #1 reason for surgery in children.  

    The Center for Disease Control suggests prescribing antibiotics for about 15% of middle ear infections. However, antibiotics are prescribed nearly 85% of the time. "Our goal is to decrease the usage of antibiotic therapy by 50% for the treatment of middle ear infections," said Caitlin Cameron, CEO OtoNexus Medical Technologies. It is an honor that MedTech Outlook recognizes how our unique technology empowers physicians to avoid unnecessary prescriptions of antibiotics and improve treatment of middle ear infections."

    The OtoNexus device has the potential to:

    • Minimize the use of unnecessary antibiotics in the treatment of middle ear infections
    • Improve patient outcomes with timely, accurate diagnosis and treatment
    • Reduce the cost of care by decreasing the number of follow up visits due to adverse antibiotics side effects and referrals to specialists

    "We have been quite impressed by OtoNexus Medical Technologies' expertise in providing infection control solutions," said Alex D' Souza, Managing Editor of MedTech Outlook magazine." We congratulate OtoNexus Medical Technologies on this prestigious recognition and look forward to seeing their impressive growth streak continue."    



    About OtoNexus Medical Technologies Inc.

    OtoNexus has developed the world's first hand-held medical device with miniaturized ultrasound technology to instantly and accurately diagnose middle ear infections. In less than 2 seconds, physicians can evaluate middle ear infections and know whether antibiotic therapy is appropriate. This definitive test will provide physicians the information they need to minimize the use of antibiotics, improve patient outcomes, and reduce the cost of care.  For more information, please visit www.otonexus.com


    About MedTech Outlook

    MedTech Outlook is a platform that bridges the spectrum between MedTech Technology providers and healthcare facilities and medical institutions.  MedTech Outlook monitors and informs about MedTech trends, challenges, and solutions.  MedTech Outlook assists purchasers/procurers, decision-makers, and heads of operations, healthcare managers from peer vetted authoritative contributions.


    About Keiretsu Forum

    Keiretsu Forum, the world’s leading angel investor network with over 1,500 investors in 38 chapters on 3 continents. Keiretsu Forum has invested more than $500 million into more than 700 companies since inception. Keiretsu Capital administers funds on behalf of its Limited Partners - the Co-Investment & Opportunities Fund creates a diversified portfolio of technology start-ups backed by top tier angel groups and pursues the high upside value potential in these dynamic investment opportunities while promoting the sharing of risk inherent in any early-stage venture.  The firm is based in Seattle and San Francisco and its principals are veteran Silicon Valley and technology investors Randy Williams, Matthew C. Le Merle, and Nathan McDonald. 

    For more information please visit www.keiretsuforum.com or contact us.

     October 06, 2020
  • Article

    Keiretsu Forum Northwest Featured by Several Major News Sources for 2015 Success

    2015 accomplishments see more

    Keiretsu Forum Northwest is delighted to be recognized by several major news source publications for their 2015 accomplishments. As a collective, Keiretsu Forum Norwest region oversaw the funding of 57 companies with over $43.5 Million in angel investing. We are honored by the recognition of this accomplishment and grateful to the following news sources for their coverage of our success. Check out the articles featuring the Kieretsu Forum Northwest investment collective.  

    Seattle Times



    Business Journal


     February 23, 2016